Nearly 300 medicines in development in USA for two leading causes of death: heart disease and stroke

3 February 2011

Drug discoveries played a major role in reducing American deaths from heart attacks and stroke by 28% between 1997 and 2007, yet cardiovascular disease still claims an American life every 39 seconds.

Working to reduce the toll further, America’s biopharmaceutical research companies are developing 299 medicines to prevent and treat heart disease and stroke, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

The report, released this week on the first day of American Heart Month, demonstrates the wide range of medicines in development for cardiovascular disease. All medicines referenced are in clinical trials or awaiting Food and Drug Administration review.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >